NYSEAMERICAN:MTNB Matinas BioPharma (MTNB) Stock Forecast, Price & News $0.13 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range N/A52-Week Range$0.11▼$0.89Volume143,943 shsAverage Volume563,152 shsMarket Capitalization$29.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort InterestSocial Media Matinas BioPharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,138.8% Upside$3.00 Price TargetShort InterestHealthy0.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 2,138.8% from its current price of $0.13.Amount of Analyst CoverageMatinas BioPharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.33% of the outstanding shares of Matinas BioPharma have been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas BioPharma has recently decreased by 38.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 1.9 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Matinas BioPharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 11.90% of the stock of Matinas BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Matinas BioPharma (NYSEAMERICAN:MTNB) StockMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.Read More MTNB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTNB Stock News HeadlinesSeptember 23, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencySeptember 22, 2023 | finance.yahoo.comMatinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencySeptember 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 15, 2023 | americanbankingnews.comMatinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest UpdateSeptember 6, 2023 | finance.yahoo.comMatinas BioPharma to Participate in the H.C. Wainwright Global Investment ConferenceAugust 22, 2023 | finance.yahoo.comMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious DiseasesAugust 11, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 10, 2023 | finance.yahoo.comQ2 2023 Matinas BioPharma Holdings Inc Earnings CallSeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 9, 2023 | finance.yahoo.comMatinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 2, 2023 | finance.yahoo.comMatinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023July 26, 2023 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023May 12, 2023 | seekingalpha.comMatinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8MMay 12, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Matinas BioPharma (MTNB)May 12, 2023 | msn.comRecap: Matinas BioPharma Hldgs Q1 EarningsMay 11, 2023 | msn.comWhy Matinas BioPharma Stock Is Sinking TodayMay 11, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comQ1 2023 Matinas BioPharma Holdings Inc Earnings CallMay 11, 2023 | finance.yahoo.comMatinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023May 10, 2023 | finance.yahoo.comMatinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue EstimatesMay 10, 2023 | finance.yahoo.comMatinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 3, 2023 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023April 28, 2023 | proactiveinvestors.comMatinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drugApril 23, 2023 | benzinga.comCTI BioPharma Stock (NASDAQ:CTIC), Analyst Ratings, Price Targets, PredictionsApril 19, 2023 | msn.comMatinas jumps 25% to hit four-month high on data for anti-fungal agentApril 18, 2023 | finance.yahoo.comCompassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDMarch 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX)See More Headlines Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MTNB Company Calendar Last Earnings8/09/2023Today9/24/2023Next Earnings (Estimated)10/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees34Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+2,138.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,000,000.00 Net Margins-479.18% Pretax Margin-641.50% Return on Equity-60.91% Return on Assets-50.22% Debt Debt-to-Equity RatioN/A Current Ratio9.27 Quick Ratio9.27 Sales & Book Value Annual Sales$3.19 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.79Miscellaneous Outstanding Shares217,260,000Free Float197,277,000Market Cap$29.11 million OptionableNot Optionable Beta2.02 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jerome D. Jabbour J.D. (Age 49)Co-Founder, CEO, Pres & Director Comp: $881.5kDr. Theresa Matkovits Ph.D. (Age 56)Chief Devel. Officer Comp: $601kDr. James J. Ferguson FACC (Age 69)M.D., Chief Medical Officer Comp: $619.92kMr. Keith A. Kucinski CPA (Age 53)M.B.A., Chief Financial Officer Dr. Hui Liu M.B.A. (Age 55)Ph.D., Chief Technology Officer Mr. Frank CalamusaExec. Director and Head of Manufacturing & Supply ChainMr. Thomas J. Hoover M.B.A. (Age 53)Chief Bus. Officer More ExecutivesKey CompetitorsForte BiosciencesNASDAQ:FBRXAgeX TherapeuticsNYSE:AGEBiora TherapeuticsNASDAQ:BIORCumberland PharmaceuticalsNASDAQ:CPIXCorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInstitutional OwnershipWells Fargo & Company MNBought 559,975 shares on 8/15/2023Ownership: 0.261%Geode Capital Management LLCBought 154,094 shares on 8/11/2023Ownership: 0.902%Sargent Investment Group LLCSold 329,000 shares on 7/31/2023Ownership: 1.806%Virtu Financial LLCBought 90,298 shares on 7/27/2023Ownership: 0.042%Neville Rodie & Shaw Inc.Sold 596,168 shares on 7/6/2023Ownership: 0.533%View All Institutional Transactions MTNB Stock - Frequently Asked Questions Should I buy or sell Matinas BioPharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MTNB shares. View MTNB analyst ratings or view top-rated stocks. What is Matinas BioPharma's stock price forecast for 2023? 1 brokerages have issued 12 month price targets for Matinas BioPharma's stock. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 2,138.8% from the stock's current price. View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts. How have MTNB shares performed in 2023? Matinas BioPharma's stock was trading at $0.5563 at the beginning of 2023. Since then, MTNB stock has decreased by 75.9% and is now trading at $0.1340. View the best growth stocks for 2023 here. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 711,500 shares, a decrease of 38.1% from the August 15th total of 1,150,000 shares. Based on an average daily trading volume, of 660,900 shares, the short-interest ratio is presently 1.1 days. View Matinas BioPharma's Short Interest. When is Matinas BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 31st 2023. View our MTNB earnings forecast. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.03) EPS for the quarter. Matinas BioPharma had a negative net margin of 479.18% and a negative trailing twelve-month return on equity of 60.91%. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS). What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.81%), Geode Capital Management LLC (0.90%), Neville Rodie & Shaw Inc. (0.53%), Wells Fargo & Company MN (0.26%) and Virtu Financial LLC (0.04%). View institutional ownership trends. How do I buy shares of Matinas BioPharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $0.13. How much money does Matinas BioPharma make? Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $29.11 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com. This page (NYSEAMERICAN:MTNB) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.